Recordati Pharmaceuticals

I've learned from them.

And I think right now what I'm focused on is particularly content generation, because even though I'm at a startup at Recordati or a mid-sized company, we have a lot of very bespoke responses, very complex questions.

Our field medical teams have very complex interactions.

And it's how do you actually create things that can compete now with the large language models that exist with the expectations of social media, bringing all that together, but still being extraordinarily robust and really adding value to that interaction, whether you're face to face or you're on a telephone, like my call centers are.

And I can only say that, for example, also maybe sharing some of the experiences of working together with you on the project.

I think what was quite outstanding also what you and the Recordati organization has achieved is that you were not just saying what you need, but you also shaped even the whole basically environment and also even made a great impact in the industry.

Because when we started...

There were no partnerships with the big publishers, right? Like we needed those integrations to M-based.

Right.

Like we saw this week with CVC Capital Partners and Group Brussels Lambert, they put out their, quote, "Best and final offer of fifty-three euros a share for Recordati."

The Italian drug maker, yeah.

Which values them at roughly ten point five billion euros.

Lower valuations mean private equity can step in, structure the deal even with higher borrowing costs, and still deliver for their partners.

Sure, I get the buyer's logic.

But if I am an existing shareholder, like in the Recordati situation, I'm not taking a lower price just because your bank loan got more expensive.

Exactly.